Ashley A. Adile
Ashley A. Adile has a total of 60 co-authors. Here are the top co-authors by number of shared publications:
- Sheila Kumari Singh
Department of Biochemistry and Biomedical Sciences, McMaster University, Hamilton, Canada
13 shared publications - Chitra Venugopal
McMaster University 2 Centre for Discovery in Cancer Research Hamilton, Canada
12 shared publications - David Bakhshinyan
McMaster Centre for Discovery in Cancer Research, McMaster University, Hamilton, Canada
12 shared publications - Yujin Suk
McMaster University Faculty of Health Sciences, Hamilton, Ontario, Canada
12 shared publications - Chirayu R. Chokshi
McMaster University 1 Department of Biochemistry and Biomedical Sciences Hamilton, Canada
11 shared publications - David Tieu
University of Toronto 8 Donnelly Centre Toronto, Canada
11 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (7)
CAN L ead: Canada as a Phase 1 Clinical Trial Leader — Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness
Background: Phase 1 oncology clinical trials have become increasingly complex, resource-intensive, but essential to modernize drug development. Despite strong academic infrastructure, Canada remains underrepresented in early-phase cancer trials relative to international peers. Methods: To advance this vision, this perspective summarizes barriers and opportunities impacting the conduct of phase 1 oncology clinical trials in Canada, based on discussions from sponsor, patient advocate, ethics, and clinical research site representatives across national major phase 1 units at the inaugural “Practical Workshop of Conducting Phase 1 Trials in Canada.” Results: Current challenges include overly restrictive and complex trial design that increases participant burden, study activation delays, operational inefficiencies, and limited access to investigational therapies following disease progression. However, Canada’s integrated academic cancer centers, publicly funded healthcare system, and ongoing advances in harmonization strategies present opportunities to strengthen national competitiveness in global site selection. Conclusion: Participant-centric strategies, earlier collaboration amongst stakeholders, and targeted operational improvements at local, provincial, and national levels are crucial to elevate Canada as a global leader (CANLead) in phase 1 oncology clinical research. Together, the approaches position Canada to advance its competitiveness and take a more prominent role on the international stage, while also providing a practical framework for developing and optimizing phase 1 units globally.
- 22 May 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (7)
Open AccessCAN L ead: Canada as a Phase 1 Clinical Trial Leader — Opportunities, Initiatives, and Collaborative Innovation to Elevate National Competitiveness
Background: Phase 1 oncology clinical trials have become increasingly complex, resource-intensive, but essential to modernize drug development. Despite strong academic infrastructure, Canada remains underrepresented in early-phase cancer trials relative to international peers. Methods: To advance this vision, this perspective summarizes barriers and opportunities impacting the conduct of phase 1 oncology clinical trials in Canada, based on discussions from sponsor, patient advocate, ethics, and clinical research site representatives across national major phase 1 units at the inaugural “Practical Workshop of Conducting Phase 1 Trials in Canada.” Results: Current challenges include overly restrictive and complex trial design that increases participant burden, study activation delays, operational inefficiencies, and limited access to investigational therapies following disease progression. However, Canada’s integrated academic cancer centers, publicly funded healthcare system, and ongoing advances in harmonization strategies present opportunities to strengthen national competitiveness in global site selection. Conclusion: Participant-centric strategies, earlier collaboration amongst stakeholders, and targeted operational improvements at local, provincial, and national levels are crucial to elevate Canada as a global leader (CANLead) in phase 1 oncology clinical research. Together, the approaches position Canada to advance its competitiveness and take a more prominent role on the international stage, while also providing a practical framework for developing and optimizing phase 1 units globally.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 2: Experimental optimization prior to clonal tacking of SU_MB002 with DNA barcoding library.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 2: Experimental optimization prior to clonal tacking of SU_MB002 with DNA barcoding library.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Data from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Purpose:Medulloblastoma is a common pediatric brain tumor with distinct molecular subgroups. Among them, group 3 medulloblastoma is associated with increased recurrence, metastatic potential, and poor patient outcomes. Small-molecule inhibitors targeting B cell–specific Moloney murine leukemia virus insertion site 1 (BMI1) have demonstrated efficacy against several types of malignant tumors, including pediatric medulloblastoma. Although our previously published in vivo study provided a promising proof of concept for the therapeutic targeting of BMI1 in group 3 medulloblastoma with small-molecule inhibitors, it is not sufficient to eradicate the tumor.Experimental Design:In this study, following preclinical validation of BMI1 inhibitor PTC596, DNA barcoding technology was leveraged to profile in vivo clonal dynamics of group 3 medulloblastoma in response to the established chemoradiotherapy regimen alone and in combination with PTC596. Following demonstration of a small number of treatment-refractory clones, we sought to identify potential druggable molecular vulnerabilities by utilizing phosphoproteomic profiling and genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening.Results:By comparing the changes in the phosphorylation pattern of key signaling kinases after PTC596 treatment with the list of sensitizer genes from in vitro genome-wide CRISPR/CRISPR-associated protein 9 screen and with the essential genes in human neural stem cells, we identified several context-specific regulators of mTOR, AKT, and PLK1 pathways. Subsequently, targeting the PI3K pathway with enzastaurin was most amenable to synergistic targeting alongside BMI1 inhibition.Conclusions:This work provides the foundation for clinical validation of small-molecule inhibitors synergistic with PTC596 to improve the durability of remissions and extend the survival of patients with treatment-refractory group 3 medulloblastoma.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Purpose:Medulloblastoma is a common pediatric brain tumor with distinct molecular subgroups. Among them, group 3 medulloblastoma is associated with increased recurrence, metastatic potential, and poor patient outcomes. Small-molecule inhibitors targeting B cell–specific Moloney murine leukemia virus insertion site 1 (BMI1) have demonstrated efficacy against several types of malignant tumors, including pediatric medulloblastoma. Although our previously published in vivo study provided a promising proof of concept for the therapeutic targeting of BMI1 in group 3 medulloblastoma with small-molecule inhibitors, it is not sufficient to eradicate the tumor.Experimental Design:In this study, following preclinical validation of BMI1 inhibitor PTC596, DNA barcoding technology was leveraged to profile in vivo clonal dynamics of group 3 medulloblastoma in response to the established chemoradiotherapy regimen alone and in combination with PTC596. Following demonstration of a small number of treatment-refractory clones, we sought to identify potential druggable molecular vulnerabilities by utilizing phosphoproteomic profiling and genome-wide clustered regularly interspaced short palindromic repeats (CRISPR) screening.Results:By comparing the changes in the phosphorylation pattern of key signaling kinases after PTC596 treatment with the list of sensitizer genes from in vitro genome-wide CRISPR/CRISPR-associated protein 9 screen and with the essential genes in human neural stem cells, we identified several context-specific regulators of mTOR, AKT, and PLK1 pathways. Subsequently, targeting the PI3K pathway with enzastaurin was most amenable to synergistic targeting alongside BMI1 inhibition.Conclusions:This work provides the foundation for clinical validation of small-molecule inhibitors synergistic with PTC596 to improve the durability of remissions and extend the survival of patients with treatment-refractory group 3 medulloblastoma.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 6: Immunohistochemical profiling of changes in phospho-AKT1 levels in response to treatment.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 6: Immunohistochemical profiling of changes in phospho-AKT1 levels in response to treatment.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 4: Assays evaluating the suitability of SU_MB002 for the in vitro genome-wide CRISPR-Cas9 screen
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 4: Assays evaluating the suitability of SU_MB002 for the in vitro genome-wide CRISPR-Cas9 screen
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 3: DNA barcode abundance
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 3: DNA barcode abundance
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 1: In vitro treatment of SU_MB002 with PTC596
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 1: In vitro treatment of SU_MB002 with PTC596
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 5: Changes in phosphorylation of select signaling kinases and distribution of gDNA across samples collected during in vitro CRISPR screen.
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 5: Changes in phosphorylation of select signaling kinases and distribution of gDNA across samples collected during in vitro CRISPR screen.
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 7: Dose response curves of small molecule inhibitors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Figure 7: Dose response curves of small molecule inhibitors
- Open Access
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Table 1: IC50 concentration of select small molecules inhibitors
- 6 January 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Leveraging Medulloblastoma Clonal Dynamics to Overcome Treatment Resistance
Supplemental Table 1: IC50 concentration of select small molecules inhibitors